Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Completed

Conditions studied: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

In brief

The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Key facts

Study ID

NCT01929408

Run by

Fred Hutchinson Cancer Center

People needed

703

Starts

2013-07-19

Expected to finish

2018-12-04

Last updated by the study team

2019-11-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms (MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:
• Present for an AML-like treatment that could plausibly produce a complete remission (CR); for example intensive induction chemotherapy, low dose single agent chemotherapy, hypomethylation agent, or a similar therapy
• Possibility to retrieve follow-up records from the collaborating institution or treating primary care physician
• Patients with primary refractory or first relapse presenting for salvage chemotherapy will be allowed
• Patients of 18 years of age or older, and are being treated by the adult AML service.
• Able to speak and read English.
• Willing and able to provide informed consent.

You may not qualify if…

• Patients of ≤17 years of age or who are 18 or older and receive treatment under the pediatric AML service.
• Patients older than 80 years
• Patients with <6 months projected survival due to active second malignancy or other medical problem.

Where it is running

• Stanford Cancer Institute — Stanford, California, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• University of Maryland — Baltimore, Maryland, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• The John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Duke University — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Pennsylvania Abramson Cancer Center — Philadelphia, Pennsylvania, United States
• University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
• SCCA Network Clinics — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.